Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fanastomig (EMB-02) in Advanced Solid Tumors
NCT04618393Phase 2Terminated
- Sponsor
- EpimAb Biotherapeutics
- Start
- Mar 2021
- Primary completion
- Jul 2023
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial in solid tumor (advanced stage) and melanoma, sponsored by EpimAb Biotherapeutics. Primary endpoints: Incidence and severity of adverse events as assessed by CTCAE V5.0, Incidence of serious adverse events and 4 more. Started Mar 2021; status: terminated.
02
Conditions
solid tumor (advanced stage)melanoma
Beyond the preview
Go deeper on NCT04618393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04618393.